Your session is about to expire
← Back to Search
CF33-CD19 + Blinatumomab for Solid Cancers (OASIS Trial)
OASIS Trial Summary
This trial studies the safety and effectiveness of combining two drugs to treat advanced solid tumors in adults.
OASIS Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowOASIS Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.OASIS Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has CF33-CD19 IT Administration Monotherapy been approved by the U.S. Federal Drug Administration?
"As this is only a Phase 1 clinical trial, limited data exists to back up the safety and efficacy of CF33-CD19 IT Administration Monotherapy; so our team determined it was suitable for a score of 1."
Are there any available slots in this research program for participants?
"Affirmative, the details on clinicaltrials.gov reveal that this investigation is currently recruiting individuals. The original listing was posted on October 2nd 2023 and recently modified on October 10th 2023. This trial requires 52 participants from one location to participate."
What are the desired outcomes of this clinical experiment?
"The main focus of this trial, which is expected to extend for the duration of 6 months from first dose to treatment discontinuation, is to identify a Recommended Phase 2 Dose (RP2D) with monotherapy. Secondary objectives include determining Duration of Response (DoR), Disease Control Rate (DCR), and Overall Response Rate (ORR)."
How many participants are currently taking part in this clinical trial?
"Affirmative. According to the current information hosted on clinicaltrials.gov, this medical trial is actively seeking participants. The experiment was first advertised on October 2nd 2023 and has since been updated as of October 10th 2023. To date, only 52 individuals have been accepted at a singular site location."
Share this study with friends
Copy Link
Messenger